A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers
The purpose of this study is to assess the safety and immunogenicity of GSK's combined
diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus
influenzae type b conjugate vaccine (DTPa-HBV-IPV/Hib) versus MCM Vaccine BV's
DTaP5-HBV-IPV-Hib vaccine administered to healthy infants and toddlers, between 6 and 12
weeks of age at the time of first vaccination, based on a 2-, 4-, and 12-months of age
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.